Zoetis Inc. (NYSE:ZTS) – Equities researchers at Gabelli raised their FY2017 earnings per share (EPS) estimates for Zoetis in a research report issued to clients and investors on Wednesday. Gabelli analyst K. Kedra now anticipates that the company will post earnings of $2.35 per share for the year, up from their prior forecast of $2.30.
Several other equities analysts have also issued reports on the company. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a research note on Monday. Deutsche Bank AG lowered Zoetis from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a research note on Tuesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research note on Friday, July 21st. Cowen and Company set a $70.00 target price on Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and an average price target of $64.78.
WARNING: “FY2017 Earnings Forecast for Zoetis Inc. (ZTS) Issued By Gabelli” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/2797501/fy2017-earnings-forecast-for-zoetis-inc-zts-issued-by-gabelli.html.
Shares of Zoetis (NYSE ZTS) opened at 60.81 on Thursday. The stock has a market capitalization of $29.85 billion, a P/E ratio of 35.35 and a beta of 1.02. The company’s 50-day moving average is $62.40 and its 200 day moving average is $57.94. Zoetis has a 12 month low of $46.86 and a 12 month high of $63.85.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 64.16%. The company had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the prior year, the firm posted $0.49 EPS. Zoetis’s revenue for the quarter was up 5.0% on a year-over-year basis.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be issued a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Tuesday, June 13th. Zoetis’s dividend payout ratio (DPR) is 23.73%.
In related news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the sale, the insider now owns 24,415 shares of the company’s stock, valued at $1,468,806.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.31% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ZTS. BlackRock Inc. increased its stake in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock worth $1,925,722,000 after buying an additional 34,679,064 shares during the period. Vanguard Group Inc. increased its stake in Zoetis by 1.7% in the first quarter. Vanguard Group Inc. now owns 32,744,421 shares of the company’s stock worth $1,747,570,000 after buying an additional 546,287 shares during the period. State Street Corp increased its stake in Zoetis by 4.9% in the first quarter. State Street Corp now owns 21,256,557 shares of the company’s stock worth $1,134,453,000 after buying an additional 986,680 shares during the period. Morgan Stanley increased its stake in Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares during the period. Finally, Clearbridge Investments LLC increased its stake in Zoetis by 4.2% in the first quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock worth $493,921,000 after buying an additional 373,568 shares during the period. 94.51% of the stock is owned by hedge funds and other institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.